Abstract:CBP and p300 are versatile transcriptional co-activators that play essential roles in regulating a wide range of signaling pathways, including Wnt/β-catenin, p53, and HIF-1α. These co-activators influence various cellular processes such as proliferation, differentiation, apoptosis, and response to hypoxia, making them pivotal in normal physiology and disease progression. The Wnt/β-catenin signaling pathway, in particular, is crucial for cellular proliferation, differentiation, tissue homeostasis, and embryogenesis. Aberrant activation of this pathway is often associated with several types of cancer, such as colorectal tumor, prostate cancer, pancreatic and hepatocellular carcinomas. In recent years, significant efforts have been directed toward identifying and developing small molecules as novel anticancer agents capable of specifically inhibiting the interaction between β-catenin and the transcriptional co-activators CBP and p300, which are required for Wnt target gene expression and are consequently involved in the regulation of tumor cell proliferation, migration, and invasion. This review summarizes the most significant and original research articles published from 2010 to date, found by means of a PubMed search, highlighting recent advancements in developing both specific and non-specific inhibitors of CBP/β-catenin and p300/β-catenin interactions. For a more comprehensive view, we have also explored the therapeutic potential of CBP/p300 bromodomain and histone acetyltransferase inhibitors in disrupting the transcriptional activation of genes involved in various signaling pathways related to cancer progression. By focusing on these therapeutic strategies, this review aims to offer a detailed overview of recent approaches in cancer treatment that selectively target CBP and p300, with particular emphasis on their roles in Wnt/β-catenin-driven oncogenesis.

P300/cyclic adenosine monophosphate response element binding protein and its biological functions

Transcriptional Regulation of Pp2a-A Alpha is Mediated by Multiple Factors Including Ap-2 Alpha, Creb, Ets-1, and Sp-1

Structure and Functions of Transcriptional Coactivators P300／cbp and Their Roles in Regulation of Interleukin Gene Expression

Distinct Roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in Nuclear Receptor Transactivation.

Progress of Transcription Factor CCAAT Enhancer Binding Protein Β

Cross-talk Between APC/C and CBP/p300.

Research progresses of transcription factor CCAAT enhancer binding protein α

Binding and modulation of p53 by p300/CBP coactivators

CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers

Co-factors p300 and CBP catch Egr1 in their network.

CBP/p300 bromodomain: new promising epigenetic target

Advances in the Research of Human CCAAT/Enhancer-binding Protein Ε

Coactivating Factors P300 and CBP Are Transcriptionally Crossregulated by Egr1 in Prostate Cells, Leading to Divergent Responses

Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors

Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation.

Co-condensation Between Transcription Factor and Coactivator P300 Modulates Transcriptional Bursting Kinetics.

Coordinated Histone Modifications Mediated by A Ctbp Co-Repressor Complex

Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents

Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment

Targeting CBP and p300: Emerging Anticancer Agents

Functional redundancy between the transcriptional activation domains of E2A is mediated by binding to the KIX domain of CBP/p300